MARKET

NEOS

NEOS

Neos
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7050
-0.0260
-3.56%
Opening 14:43 08/11 EDT
OPEN
0.7587
PREV CLOSE
0.7310
HIGH
0.7680
LOW
0.6803
VOLUME
174.82K
TURNOVER
--
52 WEEK HIGH
2.150
52 WEEK LOW
0.6000
MARKET CAP
35.07M
P/E (TTM)
-2.0323
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NEOS stock price target is 7.00 with a high estimate of 10.00 and a low estimate of 2.000.

EPS

NEOS News

More
Neos Therapeutics EPS beats by $0.02, beats on revenue
Neos Therapeutics (NASDAQ:NEOS): Q2 GAAP EPS of -$0.11 beats by $0.02. Revenue of $13.13M (-16.0% Y/Y) beats by $0.95M. Press Release
seekingalpha · 1d ago
Recap: Neos Therapeutics Q2 Earnings
Shares of Neos Therapeutics (NASDAQ:NEOS) rose 4.2% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 37.50% over the past year to ($0.11), which beat the estimate of ($0.13).Revenue of $13,133,000 decli
Benzinga · 1d ago
Neos Therapeutics Q2 EPS $(0.11) Beats $(0.13) Estimate, Sales $13.11M Beat $12.17M Estimate
Neos Therapeutics (NASDAQ:NEOS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 37.5 percent decrease over losses of $(0.08) per share from
Benzinga · 1d ago
Neos Therapeutics Reports Second Quarter 2020 Financial Results
– Company to host conference call today at 8:30 a.m. EDT –DALLAS and FORT WORTH, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focu
GlobeNewswire · 1d ago
Neos Therapeutics to Host Second Quarter 2020 Financial and Operating Results Conference Call on August 10th, 2020
DALLAS and FORT WORTH, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its seco
GlobeNewswire · 08/03 12:00
Here is What Hedge Funds Think About Neos Therapeutics Inc (NEOS)
Insider Monkey · 07/08 23:14
Edited Transcript of NEOS earnings conference call or presentation 11-May-20 9:00pm GMT
Q1 2020 Neos Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents · 07/07 19:52
Neos Therapeutics (NEOS) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/24 18:55

Industry

Pharmaceuticals
-0.15%
Pharmaceuticals & Medical Research
-0.59%

Hot Stocks

Symbol
Price
%Change

About NEOS

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.
More

Webull offers kinds of Neos Therapeutics Inc stock information, including NASDAQ:NEOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NEOS stock methods without spending real money on the virtual paper trading platform.